Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Johnson and Johnson
Mallinckrodt
McKinsey
Harvard Business School

Last Updated: August 8, 2022

Investigational Drug Information for Refametinib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Refametinib?

Refametinib is an investigational drug.

There have been 8 clinical trials for Refametinib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 16th 2013.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Neoplasms. The leading clinical trial sponsors are Bayer, Samsung Medical Center, and [disabled in preview].

There are four hundred and forty-six US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Refametinib
TitleSponsorPhase
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract AdenocarcinomaSamsung Medical CenterPhase 2
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic CancerBayerPhase 1
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)BayerPhase 2

See all Refametinib clinical trials

Clinical Trial Summary for Refametinib

Top disease conditions for Refametinib
Top clinical trial sponsors for Refametinib

See all Refametinib clinical trials

US Patents for Refametinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Refametinib See Plans and Pricing Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO) See Plans and Pricing
Refametinib See Plans and Pricing Antibody drug conjugates Novartis AG (Basel, CH) See Plans and Pricing
Refametinib See Plans and Pricing Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) See Plans and Pricing
Refametinib See Plans and Pricing Aryl-cyanoguanidine compounds Bayer Pharma Aktiengesellschaft (Berlin, DE) See Plans and Pricing
Refametinib See Plans and Pricing Organic compositions to treat beta-catenin-related diseases Arrowhead Pharmaceuticals, Inc. (Pasadena, CA) See Plans and Pricing
Refametinib See Plans and Pricing Binding molecules specific for HER3 and uses thereof MEDIMMUNE, LLC (Gaithersburg, MD) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Refametinib

Drugname Country Document Number Estimated Expiration Related US Patent
Refametinib Argentina AR077975 2029-08-28 See Plans and Pricing
Refametinib Australia AU2010286569 2029-08-28 See Plans and Pricing
Refametinib Brazil BR112012004453 2029-08-28 See Plans and Pricing
Refametinib Canada CA2771775 2029-08-28 See Plans and Pricing
Refametinib Chile CL2012000340 2029-08-28 See Plans and Pricing
Refametinib China CN102725283 2029-08-28 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Johnson and Johnson
Mallinckrodt
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.